<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02861222</url>
  </required_header>
  <id_info>
    <org_study_id>2009-017803-27</org_study_id>
    <nct_id>NCT02861222</nct_id>
  </id_info>
  <brief_title>Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma</brief_title>
  <acronym>MYOCET</acronym>
  <official_title>Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the toxicity and tolerance of Myocet® in children
      and adolescents with refractory or relapsed malignant glioma, with a dose diminished of 20%
      of the dose recommended for adults and a dose recommended for adults, administered in single
      dose in 1-hour perfusion each 21 days.

      Other purposes are to determine the recommended dose of Myocet and to assess the response to
      drug. Pharmacokinetics of doxorubicin (free and encapsulated forms) and its metabolite
      doxorubicinol during 72 hours after Myocet administration will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General health evaluation</measure>
    <time_frame>From day 21 post-dose</time_frame>
    <description>NCI-CTC scale, version 3, appendix 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in neurological condition related to the tumor (motor deficit, sensory deficit, cranial nerves pairs defect, cerebellar syndrome, vertebrobasilar defect, pyramidal tract syndrome) assessed during clinical examination</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete blood count (platelet included)</measure>
    <time_frame>2 times/week from day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ALAT/ASAT measurement</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bilirubin test</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prothrombin test</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrin measurement</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial thromboplastin time test</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine blood test</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the electrolyte composition of the blood</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood urea analysis</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemia analysis</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcemia analysis</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Protidaemia analysis</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Normality of ECG</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiography with analysis of ventricular ejection and shortening fractions</measure>
    <time_frame>From day 21 post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of initial tumors with MRI</measure>
    <time_frame>from day 42, after each 2 treatments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumoral activity (radiological criteria of SIOP protocol)</measure>
    <time_frame>from day 42, after each 2 treatments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma measurement of free doxorubicin</measure>
    <time_frame>0, 2, 5, 11, 47, 71 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma measurement of encapsulated doxorubicin</measure>
    <time_frame>0, 2, 5, 11, 47, 71 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma measurement of doxorubicinol</measure>
    <time_frame>0, 2, 5, 11, 47, 71 hours after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>MYOCET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 treatments of doxorubicin are administered at 60 mg/m²/day or 75 mg/m²/day in single dose in 1-hour perfusion each 21 days. A maximum of 6 treatments/patient is administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>MYOCET</arm_group_label>
    <other_name>MYOCET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having received at least one cycle of chemotherapy after radiotherapy

          -  Patients having grade III or IV (WHO) glioma, not localized in brainstem

          -  Tumor measurable with magnetic resonance imaging

          -  Absence of other concomitant anti-cancer treatments

          -  Absence of chemotherapy for 4 weeks; 6 weeks if nitrosourea

          -  Good general health and nutritional status according to NCI-CTC scale (version 3)
             (appendix 6)

          -  Lansky score &gt; 50% or Karnofsky &gt; 50 in children older than 12 years

          -  Absence of organ toxicity (grade &gt; 2 according to NCI-CTC criteria (version 3)

          -  Hematology: polynuclear neutrophil count &gt; 1.0 x 109/l

          -  Hematology: platelet count &gt; 100 x 109/l

          -  Liver function: bilirubinemia &lt; 1.5 normal value

          -  Liver function: ASAT and ALAT levels &lt; 2.5 normal values

          -  Liver function: prothrombin level &gt; 70%

          -  Liver function: fibrinogen &gt; 1.5 g/l

          -  Renal function: creatinemia &lt; 1.5 normal value/age

          -  Cardiac function: EF &gt; 60% and/or SF &gt; 30%

          -  Signature of informed consent by patient if adolescent, by 2 parents or legal guardian
             if minor patient

          -  For patients with childbearing potential, a contraceptive method is compulsory. This
             contraception must be continued 6 months after Myocet treatment end

          -  For patients with childbearing potential, negative pregnancy test (betahCG test)

        Exclusion Criteria:

          -  Non compliance with eligibility criteria

          -  Severe or life-threatening infection

          -  Non controlled evolutive or symptomatic intracranial hypertension

          -  History of Myocet treatment, but patients could be treated with anthracyclines if
             cardiac function is normal

          -  Hypersensibility to the active substance, to premixtures or one of excipients

          -  Pregnancy and breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Chastagner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Hémato-Oncologie pédiatrique, Hôpital d'Enfants, CHU Nancy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU, Hôpital d'Enfants de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité d'Hémato-Oncologie, CHU, Hôpital des enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU, Hôpital d'Enfants</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

